Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01632852 · ClinicalTrials.gov registry record · Phase 1

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by CSL Limited.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
5
Study locations

NCT01632852 is a Phase 1 study of Leukemia, Myeloid, Acute that has completed, run by CSL Limited. The registered enrollment target is 30 participants, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01632852, a Phase 1 study of Leukemia, Myeloid, Acute, has completed, sponsored by CSL Limited.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
5
Study locations

Study Summary

This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.

Conditions Studied

Leukemia, Myeloid, Acute

Interventions

  • BIOLOGICAL CSL362

Study Locations (5)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School - Chicago

Maryland

  • Sidney Kimmel Cancer Center at Johns Hopkins - Baltimore

New York

  • Weill Cornell Medical College - New York

Washington

  • Seattle Cancer Care Alliance - Seattle

Victoria

  • Royal Melbourne Hospital - Parkville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-07
Phase Phase 1

Sponsor

CSL Limited

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01632852

The ClinicalTrials.gov registry entry for NCT01632852 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (74% lower). The listed sponsor is CSL Limited, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 1 intervention - of which CSL362 is the first listed.

NCT01632852 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT01632852 about?

NCT01632852 is a clinical study titled "A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission". This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.

What is the current status of trial NCT01632852?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-07.

What conditions does trial NCT01632852 study?

This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.

What interventions are being tested in trial NCT01632852?

The interventions under investigation include: CSL362 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01632852?

This trial is sponsored by CSL Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01632852 being conducted?

This trial has 5 study locations across Illinois, Maryland, New York, Washington, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia, Myeloid, Acute

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia, Myeloid, Acute

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.